Gilead Sciences (GILD - Free Report) closed at $73.59 in the latest trading session, marking a +1.5% move from the prior day. This move outpaced the S&P 500's daily gain of 1.42%. At the same time, the Dow added 1.15%, and the tech-heavy Nasdaq gained 2.29%.
Coming into today, shares of the HIV and hepatitis C drugmaker had lost 2.19% in the past month. In that same time, the Medical sector lost 5.63%, while the S&P 500 lost 5.36%.
GILD will be looking to display strength as it nears its next earnings release, which is expected to be October 25, 2018. On that day, GILD is projected to report earnings of $1.64 per share, which would represent a year-over-year decline of 27.75%. Meanwhile, our latest consensus estimate is calling for revenue of $5.43 billion, down 16.67% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $6.61 per share and revenue of $21.63 billion. These totals would mark changes of -25.23% and -17.15%, respectively, from last year.
Any recent changes to analyst estimates for GILD should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. GILD is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, GILD is holding a Forward P/E ratio of 10.97. Its industry sports an average Forward P/E of 32.4, so we one might conclude that GILD is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 84, putting it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.